The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Cost-effectiveness analysis of regorafenib for metastatic colorectal cancer.
 
Daniel A. Goldstein
No Relationships to Disclose
 
Bilal B. Ahmad
No Relationships to Disclose
 
Qiushi Chen
No Relationships to Disclose
 
Turgay Ayer
No Relationships to Disclose
 
David H. Howard
Honoraria - Onyx
Travel, Accommodations, Expenses - Onyx
 
Joseph Lipscomb
No Relationships to Disclose
 
Bassel F. El-Rayes
Research Funding - AVEO; Bayer; Bristol-Myers Squibb; Kirin Pharmaceuticals; Novartis; Pfizer; Roche; Synta
 
Christopher Flowers
Consulting or Advisory Role - Algeta ASA; OptumRx; Seagen
Research Funding - Acerta Pharma (Inst); Celgene (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Infinity Pharmaceuticals (Inst); Janssen Oncology (Inst); Onyx (Inst); Pharmacyclics (Inst); Spectrum Pharmaceuticals (Inst); TG Therapeutics (Inst)
Other Relationship - Celgene